Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

This study has been completed.
Information provided by:
Innovative Medical Identifier:
First received: September 14, 2006
Last updated: September 23, 2008
Last verified: September 2008
To compare the penetration of three different NSAIDs.

Condition Intervention Phase
Drug: Nepafenac
Drug: Ketorolac LS, Bromfenac
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Innovative Medical:


Genders Eligible for Study:   Both

Inclusion Criteria:

  • Males or females scheduled to undergo Vitrectomy surgery
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00377546

United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Innovative Medical
Principal Investigator: Jeffrey Heier, MD Ophthalmic Consultants of Boston
  More Information

No publications provided Identifier: NCT00377546     History of Changes
Other Study ID Numbers: 5264
Study First Received: September 14, 2006
Last Updated: September 23, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Innovative Medical:
Retinal Surgery processed this record on November 25, 2015